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ABSTRACT
OBJECTIVES: Intralesional injection therapy with OK-432 was
developed as a therapy for operatively difficult lymphangioma
(cystic hygroma) and is currently becoming a first-choice treat-
ment for this disease. The aim of this article was to evaluate the
outcome and complications of the treatment of patients with au-
ricular hematoma by OK-432 therapy.
STUDY DESIGN: Case series with planned data collection.
SETTING: Yamagata University School of Medicine.
SUBJECTS AND METHODS: We tried this therapy in 21
patients with auricular hematoma between January 2001 and Feb-
ruary 2009. We injected OK-432 solution into the lesion with a
27-gauge needle to prevent the leak of the agent out of the hema-
toma. We performed this treatment on an outpatient basis without
hospitalization.
RESULTS: Disappearance or marked reduction of the lesion
were observed in all patients who had this therapy, and local
scarring and deformity of the auricle did not occur in any patients.
As for side effects, local pain at the injection site and fever
(37°C-38°C) were observed in a few of the patients who had this
therapy, but such problems resolved within a few days.
CONCLUSION: These results may allow us to speculate that
intralesional injection therapy with OK-432 is simple, easy, safe,
and effective and can be used as a substitute for surgery in the
treatment of auricular hematoma.
© 2010 American Academy of Otolaryngology–Head and Neck
Surgery Foundation. All rights reserved.
Auricular hematoma is commonly encountered in theotolaryngology clinic. It occurs because of blunt
trauma to the auricle, and the properly unmanaged auricular
hematoma can lead to infection, cartilage necrosis, contrac-
ture, and neocartilage formation.1-3 Although there are a
variety of treatments aimed at preventing these complica-
tions and returning the auricle to its pretrauma form, im-
proper treatment can result in the conspicuous cauliflower
ear deformity.4-12 Thus, we have developed a new, simple,
and safe method that can be used easily in private clinics
and hospitals on an outpatient basis without hospitaliza-
tion.13 This method is intralesional injection therapy with
OK-432. OK-432 (Picibanil; Chugai Pharmaceutical Co.,Received January 11, 2010; revised March 2, 2010; accepted March 3, 2010.
0194-5998/$36.00 © 2010 American Academy of Otolaryngology–Head and Nec
doi:10.1016/j.otohns.2010.03.006Tokyo, Japan) was originally developed as an immunother-
apy agent for cancer. It is thought that its immunopotenti-
ating actions are caused by strong local inflammation that
promotes the release of various cytokines. It is widely ac-
cepted that OK-432 is very effective for reduction of ascites
and pleural effusion in patients with carcinomatous perito-
nitis and pleuritis.13 When it is injected into the peritoneal
or pleural cavity, reduction of ascites and pleural effusion
occurs and adhesion of the cavity develops. Ogita et al first
reported intracystic injection therapy with OK-432 for lym-
phangioma in 1987.14 This therapy has become a treatment
of first choice for lymphangioma in Japan, because it is
effective and safe. The purpose of this article is to study the
effectiveness of intralesional injection therapy with OK-432
in patients with auricular hematoma.
Subjects and Methods
Subjects
This was a prospective clinical study of patients with au-
ricular hematoma receiving intralesional injection of OK-
432 from January 2001 to February 2009. Twenty-one pa-
tients were diagnosed as having auricular hematoma during
the study. The patients ranged from 15 to 78 years of age.
All patients were male and were treated on an outpatient
basis without hospitalization. No patients had penicillin
allergy. This study was approved by the Institutional Re-
view Board of our institution, and informed consent was
obtained from each patient.
Intralesional Injection of OK-432
We prepared 0.5 Klinische Einheit (KE) of OK-432 diluted
with 0.2 mL saline solution. We injected OK-432 solution
into the lesion with a 27-gauge needle to prevent the leak of
the agent out of the hematoma. There was no resistance in
cases of successful injection into the hematoma.
Aspiration
On the second day after the injection, the swollen auricular
hematoma was punctured by a syringe with a 20-gauge
needle, and the intralesional fluid was aspirated as much as
possible. The intralesional fluid was relatively viscous, so itk Surgery Foundation. All rights reserved.
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time.
Follow-up
All patients were regularly observed for a mean of 13.1
months (range 4-38 months) after the last injection. To treat
fever, we gave analgesics for three to five days to all
patients. Analgesics were prophylactically given to all pa-
tients in the present study to treat potential fever. The
auricular skin became red and indurated on the day after
injection, and we punctured the skin over the auricular
hematoma and aspirated the fluid on the second day after
injection. We examined all patients on days 2, 7, 14, and 28
after OK-432 injection and judged the response between
four and six weeks after injection. In case the response was
insufficient, we repeated the same therapy with a 100 per-
cent increase of OK-432. The “cure” and “marked reduc-
tion” of auricular hematoma were defined, respectively, as a
negative palpation and a decrease of more than one half
compared with pretreatment size.
Results
A total of 21 patients were enrolled in this study. The
demographic clinical data of 21 eligible patients are listed in
Table 1. The mean age of patients was 43.1 years (range
15-78 years). Maximum hematoma diameters ranged from
2.7 to 6.7 cm (mean 3.8 cm). Twenty cases of auricular
hematoma were cured (follow-up for more than 4 months
after the last injection with no recurrence) after injection
Table 1
Clinical characteristic of patients with auricular hemat
Sex Age Side Size
No. of
injections Total
1 M 52 L 3.8 cm 1 0.5
2 M 41 L 3.5 cm 2 1
3 M 72 R 4.3 cm 1 0.5
4 M 16 R 6.7 cm 5 3.5
5 M 58 L 3.2 cm 1 0.5
6 M 29 L 2.9 cm 1 0.5
7 M 17 L 2.8 cm 1 0.5
8 M 53 R 3.6 cm 1 0.5
9 M 27 L 3.9 cm 1 0.5
10 M 55 L 4.1 cm 1 0.5
11 M 15 R 5.9 cm 3 2
12 M 45 L 4.0 cm 1 0.5
13 M 58 L 3.2 cm 1 0.5
14 M 36 R 4.6 cm 1 0.5
15 M 32 R 3.8 cm 1 0.5
16 M 78 R 2.7 cm 1 0.5
17 M 45 R 3.3 cm 1 0.5
18 M 19 L 3.8 cm 1 0.5
19 M 67 L 4.1 cm 1 0.5
20 M 35 L 3.2 cm 1 0.5
21 M 55 R 2.9 cm 1 0.5
KE, Klinische Einheit.with OK-432 solution, administered one to three times. One
patient had a marked reduction of auricular hematoma, but
not a complete elimination, even after receiving the maxi-
mum of five injections of OK-432 (case number 4). The
number of treatments ranged from one to five (mean 1.3),
and mean follow-up period was 13.1 months (range from 4
to 38 months). The outcome of OK-432 injection in auric-
ular hematoma seemed not to depend on the size and loca-
tion or the patient’s age. There were no serious complica-
tions, although patients experienced fever (37.5°C-38°C )
for a few days after injection, usually controlled by antipy-
retics. No infection or abscesses developed after OK-432
injections. None of the patients had evidence of scar on the
skin at the injection site. Other side effects of the strepto-
coccal preparation, such as post–rheumatic fever sequelae
and glomerulonephritis, were not observed in any cases
(Table 2). This therapy was undertaken for all patients with
auricular hematoma on an outpatient basis without hospi-
talization.
Discussion
There are various conservative and surgical treatments for
auricular hematoma, including needle aspiration, short-term
bolsters, incision and drainage, and drainage followed by
application of a pressure dressing.1-12 Permanent elimina-
tion of the dead space after evacuation of the hematoma has
always been the main problem. Some patients are not suc-
cessfully managed, and these procedures result in the
conspicuous cauliflower ear deformity.2-12 OK-432 is a ly-
Follow-up Results Further treatment
30 months Cure None
4 months Cure None
12 months Cure None
38 months Marked reduction None
27 months Cure None
6 months Cure None
4 months Cure None
14 months Cure None
7 months Cure None
9 months Cure None
21 months Cure None
5 months Cure None
17 months Cure None
13 months Cure None
15 months Cure None
19 months Cure None
6 months Cure None
7 months Cure None
8 months Cure None
7 months Cure None























865Kubota et al Treatment of auricular hematoma by OK-432ophilized streptococcal preparation made by penicillin treat-
ment of the Su-strain of A-group streptococcus, and it was
developed as an immunotherapy agent for cancer.13 When it
is administered, strong local inflammatory reaction is
caused by activation of neutrophils and monocytes, leading
to cytokine production.15-17 Ogita et al first reported that
intralesional injection therapy with OK-432 was effective
for the lymphangioma.14 The working mechanism of OK-
432 in lymphangioma is that it immediately evokes inflam-
mation and filtration of inflammatory cells into the cystic
spaces. The accelerated lymph drainage and increased
lymph flow lead to shrinkage of the cystic spaces. We
reported that intralesional injection therapy with OK-432
was also effective in treatment of ranula.13 Roh et al have
demonstrated that sclerotherapy with OK-432 was effective
in treatment of branchial cleft cyst.18 OK-432 seems to be
more safe and effective than other sclerosing agents such as
boiling water, hypertonic saline, ethanol, tetracycline, cy-
clophosphamide, sodium morrhuate, or bleomycin. How-
ever, these sclerosing agents have shown limited success
and systemic side effects of unpredictable scarring caused
by spreading agents beyond the endothelial lining of the
hematoma. Bleomycin can cause several side effects, in-
cluding fibrosis of the lung.
Auricular hematoma arises from blunt trauma to the
auricle. Shearing forces between the anterior auricular skin
and underlying cartilage are believed to be responsible for
the hematoma.1 The location of the hematoma has been
classically described as between the perichondrium and
cartilage; however, in some patient cases, hematoma can
arise within the cartilage itself. OK-432 can induce very
strong inflammation at the injection sites in auricular hema-
toma. No deformity or infection was observed after sclero-
therapy with OK-432.13,14,18,19 The complication rate of
sclerotherapy is minimal. Sclerotherapy with OK-432 does
not require patient admission or leave any scar on the skin
at the injection site. Sclerotherapy is economically and
cosmetically more advantageous than surgery. Our study is
the first showing that auricular hematoma can be treated by
the use of OK-432 in a larger patient series. Our study was
limited by lack of a control group. Randomized controlled
trials comparing OK-432 injection with simple aspiration,
incision, or saline injection may be warranted. However, our
results may be compared with historical control groups of
simple aspiration and incision. Giles et al reported that the
recurrence rates of needle drainage, incision and drainage
with wick placement, and incision and drainage with mat-
tress suture were 75 percent, 50 percent, and 5.3 percent,
respectively.20 Needle aspiration alone and needle aspira-
tion and drain placement are not sufficient treatments. Giles
et al also reported 28 treatments in 23 ears. In the present
study, 28 treatments were performed in 21 ears; however,
18 of 21 patients required only one treatment. Schuller et al
demonstrated that only 14 of 24 patients with auricular
hematoma were successfully treated initially.8 Two suffered
reinjury requiring treatment, and these ears were reported tohave slight thickening after healing.8 From the point of cost
effectiveness, OK-432 therapy needs serial office visits,
while agent and office treatment by the other modalities
(aspiration, drainage) is considered inexpensive and re-
quires no special equipment or medication. Regarding re-
currence and number of required treatments, OK-432 ther-
apy is at least comparable to other published techniques.
There are collateral advantages regarding OK-432 therapy,
as enumerated here: 1) The time for the procedure is brief,
and it seems particularly suitable for children and other
patients who cannot tolerate long procedures. 2) No local
anesthesia was required during treatment. 3) The treatment
was painless; therefore it can be well tolerated by children
and nervous patients. 4) Secondary infection and hemor-
rhage are rare. The auricular hematoma can be primarily
treated with intralesional injection therapy with OK-432,
several times if needed. A surgical procedure is only rec-
ommended for cases with fibrous tissue and neocartilage
formation.
Conclusions
Our results suggest that the treatment of auricular hematoma
by OK-432 is simple, easy, safe, and effective therapy that
results in complete or significant decrease in the volume of
auricular hematoma, despite some incidence of recurrence.
This therapy is a potentially curative procedure that may be
used as a first-choice treatment for auricular hematoma
Table 2
Treatment characteristic and outcomes
Characteristic Results
Treatment
Previous surgery, no. (%) 1 (5)
Injected OK-432 solution
Median volume, mL (range) 0.2 (0.2-0.5)
Median dose, KE (range) 0.55 (0.5-1)
Total dose, KE (range) 0.55 (0.5-3.5)
No. of treatments, median (range) 1.3 (1-5)





Marked volume reduction  50%* 1 (5)
Minimal volume reduction  50%* 0
Recurrence after cure 0
Side effects, no. (%)
Low-grade fever 2 (10)





*Reduction of original hematoma size.before considering surgical procedures.
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